Safety, tolerability, pharmacokinetics, and pharmacodynamics of a novel kappa opioid receptor agonist ZYKR1: a randomized double-blind placebo-control phase 1 study in healthy adult human participants-Reference-Cited by-同舟云学术

Safety, tolerability, pharmacokinetics, and pharmacodynamics of a novel kappa opioid receptor agonist ZYKR1: a randomized double-blind placebo-control phase 1 study in healthy adult human participants

Published:2023-12-23 Issue: Volume: Page:
ISSN:0028-1298
Container-title:Naunyn-Schmiedeberg's Archives of Pharmacology
language:en
Short-container-title:Naunyn-Schmiedeberg's Arch Pharmacol

Author:

Kansagra Kevinkumar A.,Momin Taufik,Patel Hardik B.,Shah Chintan,Parmar Gordhan,Ghoghari Ashok,Patel Harilal V.,Parmar Deven V.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s00210-023-02912-9.pdf

Reference19 articles.

1. Albert-Vartanian A, Boyd MR, Hall AL, Morgado SJ, Nguyen E, Nguyen VP, Patel SP, Russo LJ, Shao AJ, Raffa RB (2016) Will peripherally restricted kappa-opioid receptor agonists (pKORAs) relieve pain with less opioid adverse effects and abuse potential? J Clin Pharm Ther 41(4):371–382. https://doi.org/10.1111/jcpt.12404

2. Aldrich JV, McLaughlin JP (2009) Peptide kappa opioid receptor ligands: potential for drug development. AAPS J. 11(2):312–22. https://doi.org/10.1208/s12248-009-9105-4

3. Bart G, Schluger JH, Borg L, Ho A, Bidlack JM, Kreek MJ (2005) Nalmefene induced elevation in serum prolactin in normal human volunteers: partial kappa opioid agonist activity? Neuropsychopharmacology 30(12):2254–2262. https://doi.org/10.1038/sj.npp.1300811

4. Benyamin R, Trescot AM, Datta S, Buenaventura R, Adlaka R, Sehgal N, Glaser SE, Vallejo R (2008) Opioid complications and side effects. Pain Physician 11(2 Suppl):S105–S120

5. Butelman ER, Kreek MJ (2001) Kappa-opioid receptor agonist-induced prolactin release in primates is blocked by dopamine D(2)-like receptor agonists. Eur J Pharmacol 423(2–3):243–249. https://doi.org/10.1016/s0014-2999(01)01121-9